CEPHEUS SA: A South African survey on the undertreatment of hypercholesterolaemia

Cardiovascular Journal of Africa

Volumn 22, Issue 5, 2011, Pages 234-240

  Raal, Frederick ^a   Schamroth, Colin ^b   Blom, Dirk ^c   Marx, Jan ^d   Rajput, Mangoo ^e   Haus, Matthias ^f   Hussain, Razia ^f   Cassim, Fatima ^f   Nortjé, Michelle ^f   Vandenhoven, Guy ^f   Temmerman, Anne Marie ^f  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b MILPARK HOSPITAL   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d Universitas Private Hospital   (South Africa)

^e RK Khan Hospital   (South Africa)

^f ASTRAZENECA   (United Kingdom)

Author keywords

Hypercholesterolaemia; LDL C; Lipid lowering drugs; Statins; Under treatment

Indexed keywords

ANTILIPEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE DISTRIBUTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; REVIEW; SEX DIFFERENCE; SOUTH AFRICA;

AGED; ANTICHOLESTEREMIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; AWARENESS; BIOLOGICAL MARKERS; CHOLESTEROL, LDL; DRUG UTILIZATION; FEMALE; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYPERCHOLESTEROLEMIA; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; ODDS RATIO; PATIENT EDUCATION AS TOPIC; PERCEPTION; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES; SOUTH AFRICA; TIME FACTORS; TREATMENT OUTCOME;

EID: 80054048310     PISSN: 19951892     EISSN: None     Source Type: Journal    
DOI: 10.5830/CVJA-2011-044     Document Type: Review

References (23)

1. Sans S, Kesteloot H, Kromhout D, on behalf of the Task Force. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 1997; 18: 1231-1248. (Pubitemid 27332143)
2. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br Med J 1994; 308: 367-372 (Pubitemid 24078498)
3. Law MR, Wald NJ. An ecological study of serum cholesterol and ischaemic heart disease between 1950 and 1990. Eur J Clin Nutr 1994; 48: 305-325 (Pubitemid 24141278)
4. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br Med J 2003; 326: 1423.
5. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24: 1601-1610. (Pubitemid 37012194)
6. National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and, treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and, treatment of high blood cholesterol in adults (Adult Treatment Panel III): final report. Circulation 2002; 106: 3143-3421.
7. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 2007; 28: 2375-2414. (Pubitemid 47542237)
8. Grundy SM, Cleeman JI, Merz CN, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-239. (Pubitemid 38924592)
9. Iglseder B, Moroder T, Staffen W, et al. High prevalence and undertreatment of hypercholesterolaemia in participants in a public stroke prevention programme in Austria. Clin Drug Investig 2005; 25: 709-717. (Pubitemid 41577411)
10. Diamantopoulos EJ, Athyros VG, Yfanti GK, et al., OLYMPIC study group. The control of dyslipidemia in outpatient clinics in Greece (OLYMPIC) Study. Angiology 2005; 56: 731-741. (Pubitemid 41790982)
11. EUROASPIRE II study group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Eur Heart J 2001; 22: 554-572.
12. EUROASPIRE I and II group. European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357: 995-1001.
13. Kindermann M, Adam O, Werner N, et al. Clinical Trial Updates and Hotline Sessions presented at the European Society of Cardiology Congress 2007 - EUROASPIRE III. Clin Res Cardiol 2007; 96: 767-786.
14. Malik S, Lopez V, Chen R, et al. Undertreatment of cardiovascular risk factors among persons with diabetes in the United States. Diabetes Res Clin Pract 2007; 77: 126-133. (Pubitemid 46590472)
15. Klingman D, Williams SA, Benner JS, et al. Gauging the treatment gap in dyslipidemia: findings from the 1999-2000 National Health and Nutrition Examination Survey. Am Heart J 2005; 150: 595-601. (Pubitemid 41317636)
16. Hobbs FDR. Guidelines and management of global risk: the European perspective. Eur Heart J Suppl 2004; 6(Suppl C): C5-C14. (Pubitemid 38844947)
17. Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the Metabolic Syndrome: a Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and the International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
18. Scholte op Reimer W, de Swart E, de Barcquer D, et al. for the EUROASPIRE investigators. Smoking behaviours in European patients with established heart disease. Eur Heart J 2006; 27: 35-41.
19. De Bacquer D, De Backer G, Cokkinos D, et al. for the EUROASPIRE II Study Group. Overweight and obesity in patients with established coronary heart disease: are we meeting the challenge? Eur Heart J 2004; 25: 121-128. (Pubitemid 38112150)
20. Nagashima H, Kasanuki H. The status of lipid management in 1,836 patients with coronary artery disease: A multicenter survey to evaluate the percentage of Japanese coronary artery disease patients achieving the target low-density lipoprotein cholesterol level specified by the Japan Atherosclerosis Society. J Atheroscler Thromb 2005; 12: 338-342.
21. Cholesterol Treatment Trialists' (CTT) collaborators: Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
22. Hobbs FD, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Fam Pract 2002; 19: 596-604. (Pubitemid 35460642)
23. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid lowering drugs. Med J Aust 1996; 164: 208-211. (Pubitemid 26057169)